2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab

By afschroeder • April 2, 2026

Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, Martin GS, Pearson JC, Shumaker AH, Baden LR, Bedimo R, Cheng VC, Chew KW, Daar ES, Glidden DV, Hardy EJ, Johnson S, MacBrayne C, Nakamura MM, Oliveira CR, Riley L, Shafer RW, Shoham S, Tebas P, Tien PC, Willis Z, Wolf J, Loveless J, Falck-Ytter Y, Morgan RL, Gandhi RT. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab. Clin Infect Dis. 2026 Apr 1:ciaf681. doi: 10.1093/cid/ciaf681. Epub ahead of print. PMID: 41920901.

Tags: baricitinib, covid-19, guideline, Harbor UCLA, Infectious Diseases, Publications, SARS-CoV-2, Tocilizumab

Related Posts

Continuous Glucose Monitoring and Mortality Risk Among U.S. Veterans Receiving Dialysis With Diabetes

Narasaki Y, Kalantar-Zadeh K, Zisman-Ilani Y, Klonoff DC, Kovesdy CP, Li Z, Jin A, Crowley S, M Belcher J, Gee P, Gin GE, Jordan M,[...]

Deep learning-based CT-derived vertebral bone mineral density and metformin therapy: a longitudinal study in the Multi-Ethnic Study of Atherosclerosis

Momtazmanesh S, Hathaway QA, Jannatdoust P, Ghotbi E, Bancks MP, Bluemke DA, Barr RG, Smith BM, Post WS, Budoff MJ, Lima JAC, Demehri S. Deep[...]

Racial and Ethnic Disparities in Living Donor Kidney Transplantation in California: 2010-2024

Al Ammary F, Adeyemo S, Lincoln KD, Ku E, Adey DB, Lau WL, Rhee CM, Kalantar-Zadeh K, Flores GM. Racial and Ethnic Disparities in Living[...]